Yeast beta-glucan supplement reprograms immune cells to fight cancer in mice

The research demonstrated that adding yeast beta-glucan to the diet of obese mice altered the development of early immune cells in the bone marrow. This reprogramming induced a state of trained immunity that heightened the cells' ability to respond to tumor cells. Enhanced responses were observed against colorectal, skin, and breast cancer cell challenges in the animals. Thus, a simple dietary supplement shifted innate immune function toward a more anti-tumor phenotype.

Adopting this approach would require producing the yeast beta-glucan supplement at a scale sufficient for human studies. Because the specific product used, WellmuneTM from Kerry Group, is already food-grade and sold as a dietary supplement, manufacturing and safety data are largely available. This reduces the cost and time needed to move from preclinical work to clinical trials compared with novel entities. Engineers would need to formulate dosing regimens and delivery formats that maintain the supplement's activity through the gastrointestinal tract.

The observed benefits are currently limited to mice fed a high-fat diet and challenged with specific cancer lines. It remains unclear whether the same immune reprogramming occurs in lean individuals or in humans with different metabolic profiles. Furthermore, the durability of the anti-tumor effect after cessation of supplementation has not been established. These knowledge gaps define where the approach may stop working without further investigation.